Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:


Biomarkers for Alzheimer’s disease beyond amyloid and tau

Two new biomarkers for Alzheimer’s disease include one in the blood that relates to neurodegeneration and another that reflects blood–brain barrier dysfunction and is identifiable in cerebrospinal fluid analysis.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: New early biomarkers for neurodegeneration.


  1. Preische, O. et al. Nat. Med. (2019).

  2. Nation, D.A. et al. Nat. Med. (2019).

  3. Jansen, W. J. et al. JAMA Psychiatry 75, 84–95 (2018).

    Article  Google Scholar 

  4. Ashton, N. J. et al. Biomark Med. 12, 799–812 (2018).

    Article  CAS  Google Scholar 

  5. Fagan, A. M. et al. Sci. Transl. Med. 6, 226ra230 (2014).

    Article  Google Scholar 

  6. Maia, L. F. et al. Sci. Transl. Med. 5, 194re192 (2013).

    Article  Google Scholar 

  7. Sato, C. et al. Neuron 98, 861–864 (2018).

    Article  CAS  Google Scholar 

  8. Okamura, N. et al. Clin. Transl. Imaging 6, 305–316 (2018).

    Article  Google Scholar 

  9. Cummings, J., Lee, G., Ritter, A. & Zhong, K. Alzheimers Dement. (NY) 4, 195–214 (2018).

    Google Scholar 

  10. Rasmussen, M. K., Mestre, H. & Nedergaard, M. Lancet Neurol. 17, 1016–1024 (2018).

    Article  CAS  Google Scholar 

  11. Khalil, M. et al. Nat. Rev. Neurol. 14, 577–589 (2018).

    Article  CAS  Google Scholar 

  12. Bergman, J. et al. Neurol. Neuroimmunol. Neuroinflamm. 3, e271 (2016).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Henrik Zetterberg.

Ethics declarations

Competing interests

H.Z. has served at scientific advisory boards of Roche Diagnostics, Wave, Samumed and CogRx and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures–based platform company at the University of Gothenburg. J.M.S. has received research funding and PET tracer from AVID Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly); has consulted for Roche, Eli Lilly, Biogen and Merck; received royalties from Oxford University Press and Henry Stewart Talks; given education lectures sponsored by Eli Lilly, Biogen and GE; and serves on a Data Safety Monitoring Committee for Axon Neuroscience SE.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zetterberg, H., Schott, J.M. Biomarkers for Alzheimer’s disease beyond amyloid and tau. Nat Med 25, 201–203 (2019).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing